

Supplementary Files

Metabolic Biomarkers Affecting Cell Proliferation and Prognosis in Polycythemia Vera

Table S1. Clinical characteristics of the PV patients.

Descriptive Parameters	PV (n=32)	JAK2 mutated (n=24)	JAK2 unmutated (n=8)	<i>P</i>
Gender[n(%), female/male]	9 / 23	9 / 15	0 / 8	0.07
Age[year, M(range)]	54.5 (21~77)	64 (40~77)	38.5 (21~62)	0.001
WBC[$\times 10^9/L$, M(range)]	7.595 (4.45, 20.95)	9.35 (4.45, 20.95)	6.98 (4.59, 9.1)	0.151
HGB[g/L, M(range)]	190 (167, 223)	191 (167, 216)	182 (177, 223)	0.429
PLT[$\times 10^9/L$, M(range)]	302 (111,752)	366 (111,752)	225.5 (157,394)	0.006
HCT[% , M(range)]	55.8 (49.8, 69)	57.2 (50.6, 69)	52.8 (49.8, 60.6)	0.044
JAK2 mutation burden [% , M(range)]	-	65.8 (10.4, 93.3)	-	-
JAK2 mutation[n(%)]	-	24 (75)	-	-
JAK2 V617F mutation[n(%)]	-	22 (68.75)	-	-
JAK2 exon12 mutation[n(%)]	-	2 (6.25)	-	-
CALR mutation[n(%)]	0 (0)	-	-	-
MPL mutation[n(%)]	0 (0)	-	-	-
Diabetes [n(%)]	2 (6.25)	1 (4.17)	1 (12.5)	0.444

PV: polycythemia vera; WBC: white blood cell count; HGB: hemoglobin; PLT: platelet count; NEUT: neutrophil count; HCT: hematocrit.




Figure S1. Hierarchical clustering heatmap of potential biomarkers for PV patients.




Figure S2. Heatmap of correlation between differential metabolites in PV patients and WBC, HGB, PLT and HCT at diagnosis. Spearman's correlation test, * $P < 0.05$, * $P < 0.01$.